With the national plan focused on data collection, research, reducing supply and evidence-based mitigation strategies, the goal is to reduce xylazine deaths by 15 percent in at least three of four U.S. regions by 2025, according to a White House news release.
The drug mixture is the first and only substance the Office of National Drug Control Policy has designated as an emerging threat.
Healthcare workers have struggled to treat patients because naloxone, a popular drug used to reverse opioid overdoses, is ineffective against fentanyl-xylazine, thus increasing the risk of death.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
